Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

89
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
89
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

61
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
61
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Interpreting apparent differences among the major colchicine trials for cardiovascular prevention: a descriptive compatibility analysis.

American heart journal·2026
Same author

DOAC Score Among Patients Receiving Vitamin K Antagonists.

American heart journal·2026
Same author

Impact of Animal-Assisted Therapy on Quality, Completeness, and Satisfaction in Pediatric Echocardiography.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography·2026
Same author

Patient-Centered Evaluation of Anticoagulation in Atrial Fibrillation.

NEJM evidence·2026
Same author

Comparative effectiveness of antidepressants for depression using EHRs from two health systems.

BMC psychiatry·2026
Same author

AI-Based Automation for Medication Reconciliation: Scoping Review.

Journal of medical Internet research·2026

相关实验视频

Updated: Jul 2, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K

使用机器学习优化对心房的患者的华法林剂量.

Jeremy Petch1,2,3,4, Walter Nelson5,6, Mary Wu7

  • 1Centre for Data Science and Digital Health, Hamilton Health Sciences, Hamilton, ON, Canada. petchj@hhsc.ca.

Scientific reports
|February 24, 2024
PubMed
概括

深度强化学习优化了对心房患者的华法林剂量,改善了治疗INR范围中的时间,并减少了不良事件. 这种人工智能方法在全球范围内加强了中风预防策略.

更多相关视频

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K

相关实验视频

Last Updated: Jul 2, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K

科学领域:

  • 人工智能在医学中的应用
  • 药理学和药物剂量优化 药理学和药物剂量优化
  • 临床决策支持系统 临床决策支持系统

背景情况:

  • 华法林是一种维生素K对抗剂,广泛用于心房中风预防,但由于复杂的药理动力学,它带来了挑战,往往导致低于最佳的抗凝.
  • 达到并保持国际规范化比率 (INR) 目标范围 (2.0-3.0) 对于华法林的有效性和安全性至关重要,但在临床实践中难以持续实现.

研究的目的:

  • 开发和验证一个深度强化学习 (DRL) 模型,以优化华法林剂量,最大限度地提高治疗INR范围 (TTR) 的时间.
  • 评估DRL模型在改善临床结果方面的有效性,特别是减少中风,全身栓塞或大出血的复合终点.

主要方法:

  • 为了创建DRL模型,使用了批量约束深度Q学习算法的新型半马尔科夫决策过程制定.
  • 该模型是通过3项主要临床试验 (ENGAGE AF-TIMI 48,ARISTOTLE,ROCKET AF) 的22502名华法林治疗患者的数据进行训练的.
  • 外部验证是使用RE-LY试验中5730名华法林治疗患者的数据进行的,将算法一致的剂量与TTR和临床结果进行比较.

主要成果:

  • 外部验证表明,中心级算法一致的剂量和TTR (R2 = 0.56) 之间存在显著的正相关性.
  • 算法一致剂量的10%增加与TTR的6.78%改善和复合临床结果的11%降低相关.
  • DRL算法的性能与基于规则的临床算法相当,表明其稳定性和临床应用潜力.

结论:

  • 深度强化学习算法可以有效地优化华法林剂量,以改善心房的患者治疗INR范围中的时间.
  • 基于该DRL算法实施数字临床决策支持系统有望加强华法林管理并改善全球患者的治疗结果.